Defense Stock Hensoldt Climbs 19% in a Week, but German Court Ruling Threatens Order Momentum

A German court decision challenges key procurement law provision; Hensoldt stock rallies on strong AGM and record backlog but legal risk and mixed analyst views cap upside.

A German court decision has thrown a potential wrench into the procurement acceleration that defense companies like Hensoldt had been banking on, even as the stock powered higher on the back of a strong AGM and a record order book. The Oberlandesgericht Düsseldorf ruled that a key provision of the new Bundeswehr procurement acceleration law is likely unconstitutional, arguing that the lack of suspensive effect for complaints against contract awards violates effective legal protection. The case now heads to the Federal Constitutional Court in Karlsruhe, a process that could delay the faster awarding of military contracts the industry had hoped for.

For Hensoldt, the timing is awkward. The stock has been on a tear, adding 18.85% over the past seven trading sessions and roughly 30% over ten days. On Friday, it closed at €88.06, nudging up just 0.16% on the day but sitting a whisker below the psychological €90 barrier. The rally was fueled partly by the annual general meeting held the same day, where shareholders overwhelmingly backed management's proposals. Some 67.11% of voting capital was represented, and the dividend was raised to €0.55 per share – a yield of about 0.6% based on the €88 closing price. The compensation report for 2025 was approved with 92.83% of votes, and KPMG was reappointed as auditor. CEO Oliver Dörre used the virtual gathering to underline a strong year, citing a near-doubling of order intake to €1.48 billion and a record backlog of €9.8 billion.

The first-quarter figures released earlier also point to solid operational progress. Revenue climbed 25.57% year-on-year to €496 million, while the loss per share narrowed from minus €0.26 to minus €0.16. The company is not yet profitable, but the trajectory is improving. Still, the rally has reignited a debate among analysts about whether the stock's valuation has run ahead of itself. mwb research maintains a sell recommendation, warning of significant downside risk. On the other side, Deutsche Bank rates the stock a "buy" with a €101 target, Jefferies holds a "buy" at €90, and Warburg Research is also bullish with a €91 target. The average analyst price target of €92.86 sits only marginally above the current price, suggesting limited further upside from consensus without new catalysts.

Technically, the stock is in neutral territory. The relative strength index stands at 55.4, neither overbought nor oversold. The 50-day moving average of €77.72 is well below, and the 200-day average at €83.82 has been comfortably cleared, confirming the short-term uptrend. The €90 level now acts as the next resistance, and with the stock set to trade ex-dividend on Monday, a pullback on profit-taking would not be unusual after such a sharp advance. From its 52-week low of €65.90, shares have already recovered 33.5%, though they remain 23.5% below the 52-week high of €115.10.

The legal challenge adds an extra layer of uncertainty. If the Constitutional Court ultimately strikes down the acceleration provisions, the expected speed-up in defense contracts – a key tailwind for Hensoldt – could be delayed. That said, the company's order backlog provides a solid base, and the next major reporting event – the second-quarter results on July 31, 2026 – will offer a clearer picture of execution. For now, the mix of a booming order book, a supportive AGM, and a constitutional cloud leaves investors weighing momentum against legal risk.